Bioxytran, Inc (BIXT) stock
BIXTOTCPharmaceutical PreparationsFiscal year ends December 31
$0.02−0.00 (-3.95%)
Close on Oct 19, 2026Market cap $2.56MP/E –Yield –
Bioxytran operating income
Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.
Bioxytran's operating income for the twelve months ending Jun 30, 2026 was -$3.69M. For fiscal 2025 it was -$1.84M. The highest annual figure on record is -$215.11K in fiscal 2018.
Annual operating income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$1.84M | – |
| FY2024 | Dec 31, 2024 | -$2.22M | – |
| FY2023 | Dec 31, 2023 | -$3.80M | – |
| FY2022 | Dec 31, 2022 | -$2.44M | – |
| FY2021 | Dec 31, 2021 | -$4.21M | – |
| FY2020 | Dec 31, 2020 | -$1.27M | – |
| FY2019 | Dec 31, 2019 | -$1.63M | – |
| FY2018 | Dec 31, 2018 | -$215.11K | – |
| FY2017 | Dec 31, 2017 | -$310.59K | – |
| FY2016 | Dec 31, 2016 | -$671.28K | – |
| FY2015 | Dec 31, 2015 | -$2.09M | – |
| FY2014 | Dec 31, 2014 | -$1.28M | – |
| FY2013 | Dec 31, 2013 | -$1.97M | – |
| FY2012 | Dec 31, 2012 | -$2.29M | – |
| FY2011 | Dec 31, 2011 | -$4.43M | – |
| FY2010 | Dec 31, 2010 | -$329.03K | – |
Quarterly operating income
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$654.60K | – |
| Q1 FY2026 | Mar 31, 2026 | -$1.93M | – |
| Q4 FY2025 | Dec 31, 2025 | -$607.29K | – |
| Q3 FY2025 | Sep 30, 2025 | -$496.01K | – |
| Q2 FY2025 | Jun 30, 2025 | -$224.08K | – |
| Q1 FY2025 | Mar 31, 2025 | -$515.14K | – |
| Q4 FY2024 | Dec 31, 2024 | -$488.31K | – |
| Q3 FY2024 | Sep 30, 2024 | -$346.20K | – |
| Q2 FY2024 | Jun 30, 2024 | -$609.32K | – |
| Q1 FY2024 | Mar 31, 2024 | -$779.23K | – |
| Q4 FY2023 | Dec 31, 2023 | -$1.01M | – |
| Q3 FY2023 | Sep 30, 2023 | -$985.47K | -7027.7% |
| Q2 FY2023 | Jun 30, 2023 | -$1.06M | – |
| Q1 FY2023 | Mar 31, 2023 | -$750.24K | – |
| Q4 FY2022 | Dec 31, 2022 | -$1.09M | – |
| Q3 FY2022 | Sep 30, 2022 | $14.23K | – |
| Q2 FY2022 | Jun 30, 2022 | -$537.22K | – |
| Q1 FY2022 | Mar 31, 2022 | -$819.11K | – |
| Q4 FY2021 | Dec 31, 2021 | -$935.96K | – |
| Q3 FY2021 | Sep 30, 2021 | -$547.24K | – |
| Q2 FY2021 | Jun 30, 2021 | -$1.04M | – |
| Q1 FY2021 | Mar 31, 2021 | -$1.69M | – |
| Q4 FY2020 | Dec 31, 2020 | -$776.30K | – |
| Q3 FY2020 | Sep 30, 2020 | -$114.45K | – |
| Q2 FY2020 | Jun 30, 2020 | -$111.91K | – |
| Q1 FY2020 | Mar 31, 2020 | -$266.04K | – |
| Q4 FY2019 | Dec 31, 2019 | -$499.66K | – |
| Q3 FY2019 | Sep 30, 2019 | -$850.32K | – |
| Q2 FY2019 | Jun 30, 2019 | -$106.50K | – |
| Q1 FY2019 | Mar 31, 2019 | -$129.63K | – |
| Q4 FY2018 | Dec 31, 2018 | -$166.64K | – |
| Q3 FY2018 | Sep 30, 2018 | -$47.52K | -193.5% |
| Q2 FY2018 | Jun 30, 2018 | -$275 | – |
| Q1 FY2018 | Mar 31, 2018 | -$670 | – |
| Q4 FY2017 | Dec 31, 2017 | -$86.41K | -163.0% |
| Q3 FY2017 | Sep 30, 2017 | $50.83K | – |
| Q2 FY2017 | Jun 30, 2017 | -$258.47K | – |
| Q1 FY2017 | Mar 31, 2017 | -$62.64K | – |
| Q4 FY2016 | Dec 31, 2016 | $137.23K | – |
| Q3 FY2016 | Sep 30, 2016 | -$212.04K | – |
See a number that looks wrong?